A retrospective observational study to evaluate the clinical outcomes and routine management of patients with chronic lymphocytic leukaemia treated with idelalisib and rituximab in the UK and Ireland (RETRO-idel).

British Journal of Haematology
Toby A EyreChristopher Fegan

Abstract

Idelalisib (IDL) is an oral first-in-class phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor approved for chronic lymphocytic leukaemia (CLL) alongside rituximab (R) since 2014. However, little data exist on routine practice. The RETRO-idel was a protocol-led, retrospective study of 110 patients [n = 27 front-line (1L)] who received IDL-R. The primary end-point was clinical overall response rate (ORR). The median (range) follow-up of the whole cohort was 30·2 (0·1-51·9) months. The median (range) age was 72 (48-89) years. Tumour protein p53-disruption was common [100% 1L, 32·5% relapsed/refractory (R/R)]. The best ORR (intention-to-treat) was 88·2% (1L 96·3%, R/R 85·5%). Overall, the median event-free survival (mEFS) was 20·3 months and time-to-next treatment was 29·2 months. The mEFS for 1L patients was 18·7 months and R/R patients was 21·7 months. The 3-year overall survival was 56·1% (95% confidence interval 45·7-65·3). IDL was discontinued in 87·3% (n = 96). More patients discontinued due to adverse events in the front-line setting (1L 63·0% vs. R/R 44·6%) and due to progressive disease in R/R patients (20·5% vs. 3·7% in 1L). Lower respiratory tract infection/pneumonia were reported in 34·5% (Grade ≥3, 19·1%), diarrhoea...Continue Reading

References

Jun 21, 2013·The New England Journal of Medicine·John C ByrdSusan O'Brien
Jan 24, 2014·The New England Journal of Medicine·Richard R FurmanSusan M O'Brien
Jan 24, 2014·The New England Journal of Medicine·Ajay K GopalGilles A Salles
Mar 3, 2015·Leukemia & Lymphoma·Steven E CoutréAndrew D Zelenetz
Dec 8, 2015·The New England Journal of Medicine·John C ByrdRichard R Furman
Apr 30, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A R MatoC Nabhan
Mar 22, 2018·The New England Journal of Medicine·John F SeymourArnon P Kater
Dec 7, 2018·The New England Journal of Medicine·Jennifer A WoyachJohn C Byrd
Apr 18, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jeff P SharmanStephan Stilgenbauer
Jun 6, 2019·The New England Journal of Medicine·Kirsten FischerMichael Hallek
Aug 1, 2019·The New England Journal of Medicine·Tait D ShanafeltMartin Tallman
Mar 22, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Anthony R MatoToby A Eyre
May 28, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paolo GhiaWojciech Jurczak

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.